NR1H4 and metabolic dysfunction-associated steatohepatitis: However, the drug combination did not translate into a synergistic effect on portal pressure reduction—at least in this animal model—and further studies will be necessary to dissect the impact of FXR agonists on the static and dynamic component of PH in a NASH setting.